At the last check on Friday, Moderna Inc.’s (NASDAQ:MRNA) stock was up $8.6, moving up 6.61 percent to $138.77. The average number of shares traded per day over the past five days has been 6,827,907 shares. 1 time new highs have been achieved over the past 5 days, with a $4.64 gain in that time frame. In the last twenty days, the average volume was 6,324,932, while in the previous 50 days, it was 7,121,073.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .
Since last month, MRNA stock retreated -18.39%. Shares of the company fell to $119.01 on 05/12/22, the lowest level in the past month. A 52-week high of $497.49 was reached on 01/03/22 after having rallied from a 52-week low of $119.01. Since the beginning of this year, MRNA’s stock price has dropped by -48.75% or -$114.94 and marked a new high 1 time. However, the stock has declined by -72.11% since its 52-week high.
Moderna Inc. (MRNA) last reported insider trading activity 3 days ago on May 10. Andres Juan disposed of 195 shares for $133.71 on May 10. It resulted in a $26,074 divestment by the insider. Meline David W sold 156 shares at an average price of $133.71 on May 10. The insider now owns 2,583 shares following the transaction. On May 10, President Hoge Stephen sold 234 shares at $133.71 apiece. The transaction was valued at $31,289.
Right now, Moderna Inc. (MRNA) has a P/E ratio of about 3.83. The stock’s beta is 1.70. Besides these, the trailing price-to-sales (P/S) ratio of 2.42, the price-to-book (PB) ratio of 3.06, and the price-to-cash flow ratio of 4.20 may also be considered.
In the three months ended March 30, Moderna Inc.’s quick ratio stood at 1.60, while its current ratio was 1.80, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 0.04, and the total debt-to-equity ratio was 0.05. On the profitability front, the trailing twelve-month gross margin is 84.80% percent. In the year ended March 30, operating margins totaled 71.90%. Based on annual data, MRNA earned $15.85 billion in gross profit and brought in $18.47 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 81.90%. Return on equity (ROE) for the past 12 months was 121.90%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. MRNA’s revenue rose 68.07% to $7.21 billion during the quarter, while net income inched up to $6.07 billion. While analysts expected Moderna Inc. to report $5.21 quarterly earnings, the actual figure was $8.58 per share, beating the consensus estimate by 64.70%. During the quarter, the company generated $4.32 billion in EBITDA. The liabilities of Moderna Inc. were 10.53 billion at the end of its most recent quarter ended March 30, and its total debt was $916.0 million. The value of shareholders’ equity is $397.76 million.
This quick technical analysis looks at Moderna Inc.’s (MRNA) price momentum. With a historical volatility rate of 87.92%, the RSI 9-day stood at 48.39% on 12 May.
With respect to its five-day moving average, the current Moderna Inc. price is up by +3.45% percent or $4.64. At present, MRNA shares trade -15.99% below its 20-day simple moving average and -49.69% percent below its 100-day simple moving average. However, the stock is currently trading approximately -1.76% below its SMA50 and -59.77% below its SMA200.
Stochastic coefficient K was 29.24% and Stochastic coefficient D was 19.57%, while ATR was 11.61. Given the Stochastic reading of 54.94% for the 14-day period, the RSI (14) reading has been calculated as 46.23%. As of today, the MACD Oscillator reading stands at -6.76, while the 14-day reading stands at -8.12.
Redburn upgraded its rating on Moderna Inc. (NASDAQ: MRNA) to a Neutral in a note to investors on February 01, 2022. The analysts firm previously had a Sell rating on the stock.Moderna Inc. (MRNA) has been rated Overweight by analysts. According to 1 brokerage firm, MRNA is a sell, and 10 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 3 analysts rate Moderna Inc. stock as buy, with 6 recommending it as overweight.
With a median target price of $204.50, the current consensus forecast for the stock is $80.00 – $506.00. Based on these forecasts, analysts predict Moderna Inc. (MRNA) will achieve an average price target of $233.14.